Impact of anemia on short-term outcomes after TAVR: A subgroup analysis from the BRAVO-3 randomized trial.

Victor RazukAnton CamajDavide Cao Johny NicolasChristian HengstenbergSamantha SartoriZhongjie ZhangDavid PowerFrans BeerkensMauro ChiaritoNicolas MeneveauChristophe TronNicolas DumonteilJulian D WidderMarkus FerrariRoberto VioliniPieter R StellaRaban JegerProdromos AnthopoulosRoxana Mehran George D Dangas

Published in: Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2021)

Anemia was not associated with a higher risk of NACE or major bleeding at 30 days after TAVR without modification of the treatment effects of periprocedural anticoagulation with bivalirudin versus UFH.

Keyphrases

transcatheter aortic valve replacement
aortic valve
percutaneous coronary intervention
chronic kidney disease
atrial fibrillation
iron deficiency
aortic stenosis
venous thromboembolism
direct oral anticoagulants
heart failure
acute coronary syndrome
coronary artery disease
clinical trial